WO1991014673A1 - Novel process for producing benzoic acid derivative - Google Patents
Novel process for producing benzoic acid derivative Download PDFInfo
- Publication number
- WO1991014673A1 WO1991014673A1 PCT/JP1991/000350 JP9100350W WO9114673A1 WO 1991014673 A1 WO1991014673 A1 WO 1991014673A1 JP 9100350 W JP9100350 W JP 9100350W WO 9114673 A1 WO9114673 A1 WO 9114673A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl group
- lower alkyl
- compound
- reaction
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- This method is useful for industrially producing a compound having retinoid 'activity, and a novel crystalline form useful as a medicament is used.
- the compound obtained according to the present invention has been obtained by reacting a terephthalic ⁇ -naphthylamine derivative with a terephthalic acid monoester halide and then subjecting the derivative to a deesterification reaction (Japanese Patent Laid-Open No. 6 1—7 6 4 4 0).
- Japanese Patent Laid-Open No. 6 1—7 6 4 4 0 Japanese Patent Laid-Open No. 6 1—7 6 4 4 0
- this method is not suitable for an industrial production method because it is difficult to obtain a raw material, and furthermore, the amine is harmful to the human body and requires more complicated steps.
- the target compound obtained by the method S is not necessarily suitable for formulation.
- the target compound is advantageously produced by a simple operation using a raw material which is industrially easily available, inexpensive and has no harmful effect on the human body, with good purity and yield. It provides the law.
- R 1 is a lower alkyl group or aryl group
- R 2 is a hydrogen atom or lower aryl group. Means a alkyl group.
- R 1. R 2 R 3. R 4. R 5. R 6 and R 7 have the same meanings as described above.
- R R 3 , R 4 R 5 R 5.
- R 7 and R 9 have the same meaning as described above. ).
- a lower alkyl group means an alkyl group having 1 to 4 carbon atoms, and specifically, a methyl group, an ethyl group, a butyl group, an i-butyl group, a butyl group, an i-butyl group. And a t-butyl group.
- the aryl group means a fuunyl group, a substituted fuunyl group, or the like.
- any group is possible as long as it is a group that is inert to the reaction. Examples include a alkoxy group, a lower alkoxycarbonyl group, a nitrogen atom, and a halogen atom.
- Pretend steps (a) - (.
- the Lewis acid is particularly preferred and, the amount of catalyst used raw materials ⁇ It is 0.5 to 5 moles, preferably 1 to 3 moles, more preferably 1.5 to 2 moles, per mole of silylated aniline.
- the acylated aniline and dihalobutane may be used in equimolar amounts, but either When used in excess, favorable results are obtained.
- solvent carbon disulfide, ether, ⁇ -genated hydrocarbon, di- ⁇ -gallon, or the like is used, but D-genated hydrocarbon is particularly desirable.
- the reaction can be carried out at a temperature of ⁇ 70 to 50 ° C. under heating, at room temperature or under cooling, but the reaction is preferably carried out at room temperature or under cooling.
- the reaction time, a force affected by the reaction temperature, 0.5 to 20 hours is sufficient.
- halogenating agents such as phosphorus trigen halide, oxyhalogen pyridine, phosphorus pentahalide, and thionyl halide are used, and phosphorus pentachloride is particularly preferable.
- alcohol lower alcohol is preferred, and methanol is advantageous industrially.
- reaction temperature room temperature or under cooling is employed, but the reaction under cooling is preferred.
- the hydrolysis in the step (c :) is carried out under basic conditions at room temperature or under heating conditions, but proceeds rapidly when heated.
- Japanese Patent Application Laid-Open No. Sho 61-74640 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine
- the starting material was used as a starting material, and reacted with monomethyl terephthalate ester mouth to obtain the methyl ester of the target compound.
- This was dissolved in methanol-water, and the sodium hydroxide was added thereto. And hydrolyze.
- the target compound is obtained by recrystallizing the obtained crystals from ethyl acetate-hexane by an extraction separation method.
- the methanol-based solvent means a mixed solvent of methanol or methanol-water, and methanol-water is preferably used.
- the amount of water used is preferably 0.5 to 2 times the amount of methanol, but is most preferably used in the same amount as methanol.
- the compound of the present invention is particularly required to be operated in a closed system since it has a particularly strong physiological activity. From this point of view, the method 5) of the present invention, which can be easily operated in the same container, can be said to be advantageous.
- acetanilide used as a starting material in the method of the present invention can be obtained in large quantities and is safe to handle.
- Example 3 the compound 4-1 [(5.6, 7,8-tetrahydrofuran-1,5,5,8,8-tetramethyl-methyl) obtained in Example 3 shown as an example of the method of the present invention.
- the particle size is uniform at 0.2 mm or less, but according to the known technique, the particle size is not less than Iran and non-uniform. For this reason, the powdering step can be omitted according to the method of the present invention in the case of formulation, which is very advantageous.
- the method of the present invention is industrially excellent in that the target compound can be advantageously synthesized with a simple operation, in a safe and high yield.
- thermal decomposition diagram of the synthesized target compound is melted at 1 93 e C.
- 23 3 is a pyrolysis diagram of the target compound synthesized according to a known production method. Melting at C.
- FIG. 1 is a powder X-ray diffraction chart of a target compound synthesized according to the production method of the present invention.
- Powder X-ray diffraction diagram of the target compound synthesized according to a method known in the art Powder X-ray diffraction diagram of the target compound synthesized according to a method known in the art.
- Example 12 ⁇ -14 the same reaction as in Example 1-1 was carried out under different reaction conditions to obtain the results shown in Table 3 (Example 12 ⁇ -14).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Paper (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3505852A JP3001632B2 (ja) | 1990-03-20 | 1991-03-15 | 安息香酸誘導体の新規製造法 |
EP91906248A EP0478787B1 (en) | 1990-03-20 | 1991-03-15 | Novel process for producing benzoic acid derivative |
KR1019910701646A KR960014911B1 (ko) | 1990-03-20 | 1991-03-15 | 벤조산 유도체의 신규 제조방법 |
DE69106098T DE69106098T2 (de) | 1990-03-20 | 1991-03-15 | Neuer prozess zur herstellung eines benzoesäurederivates. |
FI915445A FI915445A0 (fi) | 1990-03-20 | 1991-11-18 | Nytt foerfarande foer framstaellning av bentsoesyraderivat. |
NO914519A NO300206B1 (no) | 1990-03-20 | 1991-11-19 | Fremgangsmåte for fremstilling av terapeutisk aktive benzosyrederivater, samt bisykliske amidforbindelser |
GR950400358T GR3015138T3 (en) | 1990-03-20 | 1995-02-22 | Novel process for producing benzoic acid derivative. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7143390 | 1990-03-20 | ||
JP2/71433 | 1990-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991014673A1 true WO1991014673A1 (en) | 1991-10-03 |
Family
ID=13460393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000350 WO1991014673A1 (en) | 1990-03-20 | 1991-03-15 | Novel process for producing benzoic acid derivative |
Country Status (14)
Country | Link |
---|---|
US (1) | US5214202A (ja) |
EP (1) | EP0478787B1 (ja) |
JP (2) | JP3001632B2 (ja) |
KR (1) | KR960014911B1 (ja) |
AT (1) | ATE115946T1 (ja) |
AU (1) | AU628732B2 (ja) |
DE (1) | DE69106098T2 (ja) |
DK (1) | DK0478787T3 (ja) |
ES (1) | ES2069285T3 (ja) |
FI (1) | FI915445A0 (ja) |
GR (1) | GR3015138T3 (ja) |
HU (2) | HU210300B (ja) |
NO (1) | NO300206B1 (ja) |
WO (1) | WO1991014673A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
US7314639B2 (en) | 2000-09-01 | 2008-01-01 | Toko Pharmaceutical Ind. Co., Ltd. | Process for the production of crystals of a benzoic acid derivative |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264578A (en) | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
US5648514A (en) | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5534641A (en) | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US5675033A (en) | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
CN101200435B (zh) * | 2006-12-12 | 2011-12-07 | 江苏恒瑞医药股份有限公司 | 他米巴罗汀ⅱ型结晶的制备方法 |
WO2008120711A1 (ja) | 2007-03-30 | 2008-10-09 | Tmrc Co., Ltd. | タミバロテンカプセル剤 |
WO2009114966A1 (zh) * | 2008-03-19 | 2009-09-24 | 江苏恒瑞医药股份有限公司 | 他米巴罗汀ii型结晶的制备方法 |
CN101665449B (zh) * | 2009-09-24 | 2012-12-12 | 山东大学 | 他米巴罗汀的水溶性前药及其制备方法与应用 |
CN102633673A (zh) * | 2012-03-30 | 2012-08-15 | 上海共价化学科技有限公司 | 他米巴罗汀的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6176440A (ja) * | 1984-09-19 | 1986-04-18 | Koichi Shiyudo | 安息香酸誘導体 |
JPS63130569A (ja) * | 1986-11-07 | 1988-06-02 | エフ・ホフマン―ラ ロシユ アーゲー | カルボン酸アミド含有薬剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2500157C2 (de) * | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
US4227014A (en) * | 1978-02-27 | 1980-10-07 | American Cyanamid Company | 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof |
DK214679A (da) * | 1978-06-09 | 1979-12-10 | Chugai Pharmaceutical Co Ltd | Terephthalsyremonoamid derivater fremgangsmaade til deres fremstilling samt antiallergiske midler indeholdende disse |
US4989090A (en) * | 1989-04-05 | 1991-01-29 | Yves C. Faroudja | Television scan line doubler including temporal median filter |
-
1991
- 1991-03-15 DK DK91906248.9T patent/DK0478787T3/da active
- 1991-03-15 ES ES91906248T patent/ES2069285T3/es not_active Expired - Lifetime
- 1991-03-15 DE DE69106098T patent/DE69106098T2/de not_active Expired - Lifetime
- 1991-03-15 WO PCT/JP1991/000350 patent/WO1991014673A1/ja active IP Right Grant
- 1991-03-15 JP JP3505852A patent/JP3001632B2/ja not_active Expired - Lifetime
- 1991-03-15 AU AU74826/91A patent/AU628732B2/en not_active Ceased
- 1991-03-15 EP EP91906248A patent/EP0478787B1/en not_active Expired - Lifetime
- 1991-03-15 HU HU9202856A patent/HU210300B/hu not_active IP Right Cessation
- 1991-03-15 AT AT91906248T patent/ATE115946T1/de not_active IP Right Cessation
- 1991-03-15 KR KR1019910701646A patent/KR960014911B1/ko not_active IP Right Cessation
- 1991-03-15 US US07/778,985 patent/US5214202A/en not_active Expired - Lifetime
- 1991-03-15 HU HU913801A patent/HU208417B/hu not_active IP Right Cessation
- 1991-11-18 FI FI915445A patent/FI915445A0/fi unknown
- 1991-11-19 NO NO914519A patent/NO300206B1/no not_active IP Right Cessation
-
1995
- 1995-02-22 GR GR950400358T patent/GR3015138T3/el unknown
-
1999
- 1999-07-16 JP JP11203717A patent/JP3076569B2/ja not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6176440A (ja) * | 1984-09-19 | 1986-04-18 | Koichi Shiyudo | 安息香酸誘導体 |
JPS63130569A (ja) * | 1986-11-07 | 1988-06-02 | エフ・ホフマン―ラ ロシユ アーゲー | カルボン酸アミド含有薬剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314639B2 (en) | 2000-09-01 | 2008-01-01 | Toko Pharmaceutical Ind. Co., Ltd. | Process for the production of crystals of a benzoic acid derivative |
US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
Also Published As
Publication number | Publication date |
---|---|
NO914519L (no) | 1992-01-07 |
HU208417B (en) | 1993-10-28 |
KR960014911B1 (ko) | 1996-10-21 |
HUT61272A (en) | 1992-12-28 |
EP0478787A1 (en) | 1992-04-08 |
HU913801D0 (en) | 1992-07-28 |
NO300206B1 (no) | 1997-04-28 |
HUT61270A (en) | 1992-12-28 |
ES2069285T3 (es) | 1995-05-01 |
DE69106098D1 (de) | 1995-02-02 |
US5214202A (en) | 1993-05-25 |
GR3015138T3 (en) | 1995-05-31 |
KR920702342A (ko) | 1992-09-03 |
HU9202856D0 (en) | 1992-11-30 |
EP0478787B1 (en) | 1994-12-21 |
JP2000034262A (ja) | 2000-02-02 |
FI915445A0 (fi) | 1991-11-18 |
JP3076569B2 (ja) | 2000-08-14 |
ATE115946T1 (de) | 1995-01-15 |
NO914519D0 (no) | 1991-11-19 |
EP0478787A4 (en) | 1992-07-01 |
DK0478787T3 (da) | 1995-02-20 |
HU210300B (en) | 1995-03-28 |
DE69106098T2 (de) | 1995-05-24 |
JP3001632B2 (ja) | 2000-01-24 |
AU628732B2 (en) | 1992-09-17 |
AU7482691A (en) | 1991-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991014673A1 (en) | Novel process for producing benzoic acid derivative | |
JPH0395144A (ja) | アミノフェノール誘導体の製造方法 | |
JPH10114704A (ja) | レイン及びジアセレインの製造法 | |
JPS5848545B2 (ja) | シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ | |
JPS5967281A (ja) | 3−メチルフラボン−8−カルボン酸誘導体及びその製造法 | |
JPS63258442A (ja) | テトラフルオロフタル酸の製造方法 | |
JP2002047270A (ja) | N−ヒドロキシイミドの製造方法 | |
JPH05132447A (ja) | (2−ヒドロキシフエニル)酢酸の製造方法 | |
JP3640319B2 (ja) | ベンズアミド誘導体の製造方法 | |
WO1991003460A1 (en) | New route of synthesis for tertiary alkyl esters | |
US2623065A (en) | Methods for producing alkoxynaphthoylalkanoic acids | |
JP4213244B2 (ja) | ケト酸の精製方法 | |
JPS5965039A (ja) | 2,4−ジヒドロキシアセトフエノンの製造方法 | |
JPH0586042A (ja) | 2−メルカプト−フエノチアジンの製造方法 | |
JPS6032756A (ja) | Ν−(cis−3,4−ジメトキシシンナモイル)アントラニル酸の製造方法 | |
JP2526413B2 (ja) | アルキレンジフェニルジスルホニルフルオライドおよびその合成方法 | |
JP4893903B2 (ja) | ブロモイソフタル酸化合物の製造方法 | |
US3916013A (en) | Substituted-o-hydroxy-omega-(methylsulfinyl-acetophenones and process for producing same | |
JPH0753704B2 (ja) | フェニルマロン酸モノアニリド誘導体および3―フェニル―2―キノロン誘導体の製造方法 | |
JP4143295B2 (ja) | 9,9−二置換−2,3,6,7−キサンテンテトラカルボン酸二無水物の製造方法 | |
JP2003119184A (ja) | 置換ピペラジニルメチル芳香族酸誘導体の製造方法 | |
JPH03275641A (ja) | ヒドロキシビフェニル化合物及びその製造法 | |
JPS63255259A (ja) | 非対称スルホンの製造方法 | |
JPH0128013B2 (ja) | ||
JP2003064039A (ja) | o−シアノアニリン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 915445 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991906248 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991906248 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991906248 Country of ref document: EP |